TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia

Journal of the National Cancer Institute

Volumn 96, Issue 4, 2004, Pages 294-305

  Steenbergen, Renske D M ^a   Kramer, Debbie ^a   Braakhuis, Boudewijn J M ^a   Stern, Peter L ^b   Verheijen, René H M ^a   Meijer, Chris J L M ^a   Snijder, Peter J F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; COMPLEMENTARY DNA; DNA; MESSENGER RNA; TUMOR SUPPRESSOR PROTEIN;

ALLELE; ARTICLE; CANCER INVASION; CARCINOGENESIS; CARCINOGENICITY; CELL GROWTH; CONTROLLED STUDY; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE SILENCING; GENETIC ANALYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; MALIGNANT TRANSFORMATION; MICROSATELLITE MARKER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; TUMOR CELL LINE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX EPITHELIUM; VIRUS INFECTION; WART VIRUS;

EID: 1342291107     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh031     Document Type: Article

References (42)

1. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97:72-81.
2. Richart RM. Causes and management of cervical intraepithelial neoplasia. Cancer 1987;60:1951-9.
3. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
4. zur Hansen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
6. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
7. Chen TM, Pecoraro G, Defendi V. Genetic analysis of in vitro progression of human papillomavirus-transfected human cervical cells. Cancer Res 1993;53:1167-71.
8. Scheffner M, Romanczuk H, Münger K, Huibregtse JM, Mietz JA, Howley PM. Functions of human papillomavirus proteins. In: Zur Hausen H, editor. Human pathogenic papillomaviruses-current topics in microbiology and immunology. Vol 186. Berlin (Germany): Springer-Verlag; 1994. p. 83-99.
9. Hurlin PJ, Smith PP, Perez-Reyes N, Blanton RA, McDougall JK. Progression of human papillomavirus type 18-immortalized human keratinocytes to a malignant phenotype. Proc Natl Acad Sci U S A 1991;88:570-4.
10. Pecoraro G, Lee M, Morgan D, Defendi V. Evolution of in vitro transformation and tumorigenesis of HPV16 and HPV18 immortalized primary cervical epithelial cells. Am J Pathol 1991;138:1-8.
11. Backsch C, Wagenbach N, Nonn M, Leistritz S, Stanbridge E, Schneider A, et al. Microcell-mediated transfer of chromosome 4 into HeLa cells suppresses telomerase activity. Genes Chromosomes Cancer 2001;31:196-8.
12. Steenbergen RD, Kramer D, Meijer CJ, Walboomers JM, Trott DA, Cuthbert AP, et al. Telomerase suppression by chromosome 6 in a human papillomavirus type 16-immortalized keratinocyte cell line and in a cervical cancer cell line. J Natl Cancer Inst 2001;93:865-72.
13. Poignee M, Backsch C, Beer K, Jansen L, Wagenbach N, Stanbridge EJ, et al. Evidence for a putative senescence gene locus within the chromosomal region 10p14-p15. Cancer Res 2001;61:7118-21.
14. Saxon PJ, Srivatsan ES, Stanbridge EJ. Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. EMBO J 1986;5:3461-6.
15. Koi M, Morita H, Yamada H, Saboh H, Barrett JC, Oshimura M. Normal human chromosome 11 suppresses tumorigenicity of human cervical tumor cell line SiHa. Mol Carcinog 1989;2:12-21.
16. Jesudasan RA, Rahman RA, Chandrashekharappa S, Evans GA, Srivatsan ES. Deletion and translocation of chromosome 11q13 sequences in cervical carcinoma cell lines. Am J Hum Genet 1995;56:705-15.
17. Srivatsan ES, Misra BC, Venugopalan M, Wilczynski SP. Loss of alleles on chromosome 11 in cervical carcinoma. Am J Hum Genet 1991;49:868-77.
18. Srivatsan ES, Chakrabarti R, Zainabadi K, Pack SD, Benyamini P, Mendonca MS, et al. Localization of deletion to a 300 Kb interval of chromosome 11q13 in cervical cancer. Oncogene 2002;21:5631-42.
19. Hampton GM, Penny LA, Baergen RN, Larson A, Brewer C, Liao S, et al. Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. Proc Natl Acad Sci U S A 1994;91:6953-7.
20. Bethwaite PB, Koreth J, Herrington CS, McGee JO. Loss of heterozygosity occurs at the D11S29 locus on chromosome 11q23 in invasive cervical carcinoma. Br J Cancer 1995;71:814-8.
21. Pulido HA, Fakruddin MJ, Chatterjee A, Esplin ED, Beleno N, Martinez G, et al. Identification of a 6-cM minimal deletion at 11q23.1-23.2 and exclusion of PPP2R1B gene as a deletion target in cervical cancer. Cancer Res 2000;60:6677-82.
22. O'Sullivan MJ, Rader JS, Gerhard DS, Li Y, Trinkaus KM, Gersell DJ, et al. Loss of heterozygosity at 11q23.3 in vasculoinvasive and metastatic squamous cell carcinoma of the cervix. Hum Pathol 2001;32:475-8.
23. Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, Ghosh HP, et al. TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 2001;27:427-30.
24. Masuda M, Yageta M, Fukuhara H, Kuramochi M, Maruyama T, Nomoto A, et al. The tumor suppressor protein TSLC1 is involved in cell-cell adhesion. J Biol Chem 2002;277:31014-9.
25. Steenbergen RD, Walboomers JM, Meijer CJ, van der Raaij-Heimer EM, Parker JN, Chow LT, et al. Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q. Oncogene 1996;13:1249-57.
26. Brady CS, Bartholomew JS, Burt DJ, Duggan-Keen MF, Glenville S, Telford N, et al. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 2000;55:401-1.
27. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5/GP6 mediated PCR immunoassay method for rapid detection of 14 high risk and 6 low risk human papillomavirus genotypes in cervical scrapes. J Clin Microbiol 1997;35:791-5.
28. Zielinski GD, Snijders PJ, Rozendaal L, Voorhorst FJ, van der Linden HC, Runsink AP, et al. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 2001;85:398-404.
29. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, et al. POBASCAM, a population-based randomised controlled trial for implementation of high-risk HPV testing in cervical screening; Design, methods and baseline data of 44,102 women. Int J Cancer. In press 2004.
30. Westerman BA, Neijenhuis S, Poutsma A, Steenbergen RD, Breuer RH, Egging M, et al. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features. Clin Cancer Res 2002;8:1082-6.
31. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 1992;89:1827-31.
32. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991;252:706-9.
33. Braakhuis BJ, Ruiz van Haperen VW, Welters MJ, Peters GJ. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 1995;31A: 2335-40.
34. Steenbergen RD, Parker JN, Isern S, Snijders PJ, Walboomers JM, Meijer CJ, et al. Viral E6-E7 transcription in the basal layer of organotypic cultures without apparent p21cip1 protein procedes immortalization of human papillomavirus type 16- and 18-transfected human keratinocytes. J Virol 1998;72:749-57.
35. Snijders PJ, van Duin M, Walboomers JM, Steenbergen RD, Risse EK, Helmerhorst TJ, et al. Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lessions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Cancer Res 1998;58: 3812-8.
36. Wisman GB, De Jong S, Meersma GJ, Helder MN, Hollema H, de Vries EG, et al. Telomerase in (pre)neoplastic cervical disease. Hum Pathol 2000;31:1304-12.
37. van Duin M, Steenbergen RD, De Wilde J, Helmerhorst TJ, Verheijin RH, Risse EK, et al. Telomerase activity in high-grade cervical lesions is associated with allelic inbalance at 6Q14-22. Int J Cancer 2003;105:577-82.
38. Fukuhara H, Kuramochi M, Fukami T, Kasahara K, Furuhata M, Nobukuni T, et al. Promoter methylation of TLSC1 and tumor suppressiom by its gene product in human prostate cancer. Jpn J Cancer Res 2002;93:605-9.
39. Jansen M, Fukushima N, Rosty C, Walter K, Altink R, Heek TV, et al. Abberant methylation of the 5′ CpG island of TLSC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade Pan-1Ns. Cancer Biol Ther 2002;1:293-6.
40. Honda T, Tamura G, Waki T, Jin Z, Sato K, Motoyama T, et al. Hypermethylation of the TSLC1 gene promoter in primary gastric cancers and gastric cancer cell lines. Jpn J Cancer Res 2002;93:857-60.
41. Allinen M, Peri L, Kujala S, Lahti-Domenici J, Outila K, Karpinnen SM, et al. Analysis of 11q21-24 loss of heterozygosity candidate target genes in breast cancer: indications of TSLC1 promoter hypermethylation. Genes Chromosomes Cancer 2002;34:384-9.
42. Baker SG, Kramer BS, Srivastava S. Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol 2002;2:4.